A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Argenx Se stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 8,672 shares of ARGX stock, worth $4.89 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,672
Previous 10,791 19.64%
Holding current value
$4.89 Million
Previous $4.64 Million 1.36%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$434.22 - $551.9 $920,112 - $1.17 Million
-2,119 Reduced 19.64%
8,672 $4.7 Million
Q2 2024

Jul 19, 2024

SELL
$356.01 - $451.55 $1.17 Million - $1.48 Million
-3,274 Reduced 23.28%
10,791 $4.64 Million
Q1 2024

Apr 22, 2024

SELL
$356.95 - $413.29 $144,564 - $167,382
-405 Reduced 2.8%
14,065 $5.54 Million
Q4 2023

Jan 16, 2024

BUY
$338.91 - $506.01 $1.14 Million - $1.71 Million
3,374 Added 30.41%
14,470 $5.5 Million
Q3 2023

Oct 24, 2023

BUY
$369.35 - $548.43 $560,673 - $832,516
1,518 Added 15.85%
11,096 $5.46 Million
Q2 2023

Jul 25, 2023

SELL
$360.14 - $422.58 $466,741 - $547,663
-1,296 Reduced 11.92%
9,578 $3.73 Million
Q1 2023

Apr 14, 2023

SELL
$334.23 - $403.65 $107,622 - $129,975
-322 Reduced 2.88%
10,874 $4.05 Million
Q4 2022

Feb 08, 2023

BUY
$342.17 - $402.31 $585,110 - $687,950
1,710 Added 18.03%
11,196 $4.24 Million
Q3 2022

Oct 25, 2022

BUY
$343.2 - $395.75 $920,805 - $1.06 Million
2,683 Added 39.44%
9,486 $3.35 Million
Q2 2022

Aug 12, 2022

BUY
$269.58 - $378.88 $878,561 - $1.23 Million
3,259 Added 91.96%
6,803 $2.58 Million
Q1 2022

May 11, 2022

BUY
$254.45 - $351.06 $283,966 - $391,782
1,116 Added 45.96%
3,544 $1.12 Million
Q4 2021

Feb 08, 2022

BUY
$272.01 - $353.03 $660,440 - $857,156
2,428 New
2,428 $850,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.